Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pSG2.HIVconsv + Ad35-GRIN + MVA.HIVconsv
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This experimental HIV vaccine regimen, developed by Ichor Medical Systems in collaboration with the University of Oxford, utilizes a heterologous prime-boost strategy. The regimen consists of a DNA vaccine (pSG2.HIVconsv) encoding highly conserved regions of the HIV-1 proteome, delivered via Ichor's TriGrid electroporation system to enhance cellular uptake and immunogenicity. This is followed by viral vector boosts using Ad35-GRIN (adenovirus 35) and MVA.HIVconsv (Modified Vaccinia Ankara). By targeting conserved regions of the virus that are less prone to mutation, the vaccine aims to elicit broad and potent T-cell immune responses. The TriGrid system is an integrated, automated device designed to improve the potency of DNA vaccines compared to conventional intramuscular injection by using electrical pulses to facilitate the entry of DNA into cells.
- Other names
- HIVconsv vaccine regimenTriGrid HIV DNA vaccine regimen
02
Targets
HIV-1 conserved region antigen
Beyond the preview
Go deeper on pSG2.HIVconsv + Ad35-GRIN + MVA.HIVconsv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pSG2.HIVconsv + Ad35-GRIN + MVA.HIVconsv.